Public CompanyPiramal Life Sciences to invest Rs 200 cr in R&D
Piramal Life Sciences, a research and development (R&D) arm of Piramal Group is investing Rs 200 crore in the next two year"s period for its ambitious programme to discover and develop new chemical entitities (NCEs) and Novel Drug Delivery Systems (NDDSs), a top company official said here.
"Piramal Life Sciences has embarked upon an ambitious programme to discover and develop new chemical entitities (NCEs) and Novel Drug Delivery Systems (NDDSs) in select therapeutic areas, including cancer, inflammation, diabetes/metabolic disorders and infectious diseases with a pipeline of 14 molecules in different phases of development," Piramal Healthcare Director, Swati Piramal told PTI here.
"Piramal Healthcare pharma hopes to maintain 30 per cent growth. During the Q4FY09, the company grew by 25 per cent in domestic pharma market," Piramal said.
Piramal Healthcare"s pharma solution division carrying out custom manufacturing for global innovator pharmaceutical companies since 2003. The group has invested about Rs 450 crore in Indian and Rs 338 crore in international assets to scale-up this business during last six years period.
Charting roadmap for the future, pharma solution division aims to cater to end-patient oriented solutions with formulations and packaging innovations.
The approach adopted is to keep the cost competitiveness of its Indian assets at the core, and then build a global outsourcing business around these assets.
Piramal Group"s diagnostic services division offers a full range of clinical diagnostic services. It is the largest player in this field and operates 90 centres spread across 57 locations in India.
Piramal Diagnostic Services serves all segments in this business and is the leader in each.
The aim of diagnostic services is to be present, in the next two years, in all cities with a population of one million or more, Piramal said.